Expertise in
7
conditions

Dr. Jairam Krishnamurthy

Hematology
Village Pointe Cancer Center
111 N 175th St, 
Omaha, NE 
Expertise in
7
conditions
Village Pointe Cancer Center
111 N 175th St, 
Omaha, NE 

Overview

Jairam Krishnamurthy is a Hematologist practicing medicine in Omaha, Nebraska.

Dr. Krishnamurthy is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Liver Embolization.

He is actively involved in clinical research, co-authoring 37 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NE

Hospital Affiliations

University Of Utah Hospital And Clinics
The Nebraska Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 15 Less Insurance Carriers -

Locations

Village Pointe Cancer Center
111 N 175th St, Omaha, NE 68118
Other Locations
Fred & Pamela Buffett Cancer Center-Nebraska Medical Center
505 S 45th St, Omaha, NE 68198

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: March 23, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase II Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy for Post and Pre-menopausal Patients With Early Stage Hormone Receptor Positive and Her-2/Neu Negative Breast Cancer
A Phase II Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy for Post and Pre-menopausal Patients With Early Stage Hormone Receptor Positive and Her-2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug
Study Drug: Palbociclib
Study Phase: Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug, Procedure
Study Drugs: Palbociclib, Letrozole, Fulvestrant, Goserelin
Study Phase: Phase 2
View 6 Less Clinical Trials

37 Total Publications

Correction: Pan et al. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals 2025, 18, 1159.
Correction: Pan et al. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals 2025, 18, 1159.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 03, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology | Oncology
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology | Oncology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (826.2 miles away)
402-559-5600
Experience:
42+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Julie Vose is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. She has been practicing medicine for over 42 years. Dr. Vose is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
38
conditions
Dr. Matthew A. Lunning
Hematology
Expertise in
38
conditions
Dr. Matthew A. Lunning
Hematology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (826.2 miles away)
402-559-5600
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Lunning is a Hematologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 20 years. Dr. Lunning is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, T-Cell Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
24
conditions
Dr. Vijaya R. Bhatt
Hematology | Oncology
Expertise in
24
conditions
Dr. Vijaya R. Bhatt
Hematology | Oncology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (826.2 miles away)
402-559-5600
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vijaya Bhatt is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 18 years. Dr. Bhatt is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Jairam Krishnamurthy

How do I make an appointment with Dr. Jairam Krishnamurthy?

You can book an appointment with Dr. Jairam Krishnamurthy by calling their office at 402-596-3100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jairam Krishnamurthy a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jairam Krishnamurthy is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jairam Krishnamurthy specialize in?

While Dr. Jairam Krishnamurthy is a Hematology, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jairam Krishnamurthy participate in research or clinical trials?

Yes. Dr. Jairam Krishnamurthy has published 37 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Jairam Krishnamurthy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jairam Krishnamurthy accept my insurance?

Dr. Jairam Krishnamurthy accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 402-596-3100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krishnamurthy's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile